Targeted therapy for early-stage HER2-positive breast cancer continues to show benefit

https://www.facingourrisk.org/XRAY/target-therapy-for-early-HER2-positive-breast-cancer

Full article: https://medically.roche.com/content/dam/pdmahub/restricted/oncology/sabcs-2023/SABCS-2023-presentation-loibl-phase-iii-study-of-adjuvant-ado.pdf

People with early-stage HER2-positive breast cancer benefit from targeted therapy. This update includes new data on survival and the length of time without cancer returning. (Posted 6/20/24)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Is my cancer HER2-positive?
Is trastuzumab emtansine (T-DM1) an option for me? If not, which treatment do you recommend and why?
What are the side effects of T-DM1? What can I do to prevent or treat them?
What is the risk of recurrence after T-DM1 treatment?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.